Search results for PX-TA1032

Tixagevimab Biosimilar – Anti-Covid Spike RBD mAb – Research Grade, ProteoGenix, PX-TA1032

Description of Tixagevimab Biosimilar - Anti-Covid Spike RBD mAb - Research Grade Tixagevimab is a monoclonal antibody targeting spike protein of SARS-CoV-2. This humanized biosimilar belong to the family of immunoglobulin G1- type. Tixagevimab has been recently approved by FDA and EMA to be used in emergency as prophylactic treatment against COVID-19 in association with cilgavimab. About the Spike protein The spike protein is a transmembrane viral fusion protein. Spike has a homotrimeric structure and each monomere is composed of two subunits: S1 and S2. The S1 part is carrying the Receptor Binding Domain (RBD), and the S2 part is responsible of the fusion of the virus with the cellular membrane. The RBD Part of S1 is binding the Angiotensin Converting Enzyme 2 (ACE2) in the organism. A research grade biosimilar Tixagevimab biosimilar is a humanized antibody based on cross Mab technology. It is produced in mammalian cell line (Chinese Hamster Ovary -CHO) using a recombinant DNA technology. Proteogenix offer a product for research use only, not suitable for clinical or therapeutic use Proteogenix launched a panel of antibodies against SARS-CoV-2 spike and the nucleocapsid. Each of them can recognize specifically SARS-CoV-2 antigens without cross reactivity with other human coronaviruses. Neutralizing antibodies are very promising in antiviral defense against the coronavirus disease 2019 (COVID-19) pandemic.